GlassScriptPhysician profile
Jay A Van Gerpen
NPI 1174585590
$14,636.04
in general payments reported to CMS, 2019-2025
64 companies · $3,356 in 2025
The $3,356 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $1,137 · 2022: $2,487 · 2023: $3,968 · 2024: $3,578 · 2025: $3,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,875.26 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,198.50 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,105.95 | 2021-2025 | Briviact, Rystiggo, Zilbrysq |
| Argenx US, INC. | $819.76 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $679.71 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $606.87 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $587.03 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $580.86 | 2022-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $557.67 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $527.02 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Sk Life Science, INC. | $519.29 | 2021-2025 | |
| Tg Therapeutics, INC. | $482.36 | 2023-2025 | |
| Genentech USA, INC. | $440.49 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $439.80 | 2021-2025 | |
| Amgen INC. | $415.32 | 2021-2025 | Uplizna, Aimovig |
| Acorda Therapeutics, INC | $374.84 | 2021-2023 | Inbrija |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $365.09 | 2021-2025 | Valtoco |
| Mdd US Operations, LLC | $360.23 | 2023-2024 | Gocovri, Gocovri |
| Lundbeck LLC | $315.49 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $233.27 | 2021-2024 | |
| Emd Serono, INC. | $177.32 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $171.84 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $144.62 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Catalyst Pharmaceuticals, INC. | $144.35 | 2022-2025 | Fycompa |
| Celgene Corporation | $143.32 | 2022-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $138.64 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $131.78 | 2021-2025 | Leqembi, Vumerity, Tysabri |
| Takeda Pharmaceuticals U.S.A., INC. | $124.41 | 2023-2025 | Hyqvia |
| Biohaven Pharmaceutical Holding Company LTD. | $122.86 | 2022 | |
| Avanir Pharmaceuticals, INC. | $122.82 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $122.53 | 2023 | Aptiom |
| Kyowa Kirin, INC. | $119.31 | 2022-2024 | Nourianz |
| Csl Behring | $113.63 | 2020-2023 | Hizentra |
| Scilex Pharmaceuticals INC. | $104.40 | 2023-2024 | Ztlido |
| Octapharma USA, INC. | $103.31 | 2024-2025 | Panzyga |
| Adamas Pharmaceuticals, INC. | $102.93 | 2020-2021 | |
| Grifols USA, LLC | $94.23 | 2022-2024 | Gamunex-C |
| Greenwich Biosciences, INC. | $66.23 | 2021 | |
| Axsome Therapeutics, INC. | $65.63 | 2023-2025 | Sunosi, Symbravo |
| Horizon Therapeutics Plc | $61.56 | 2023 | Uplizna |
| Impel Pharmaceuticals INC. | $52.82 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $52.32 | 2021-2025 | Crexont |
| Jazz Pharmaceuticals INC. | $49.65 | 2022-2024 | |
| C2n Diagnostics, LLC | $39.86 | 2025 | Precivityad2 |
| Immedica Pharma US, INC. | $39.05 | 2023-2024 | |
| Harmony Biosciences LLC | $36.63 | 2022-2023 | Wakix |
| Astrazeneca Pharmaceuticals LP | $32.90 | 2024 | Wainua, Andexxa |
| Boston Scientific Corporation | $30.90 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $29.55 | 2021 | |
| Janssen Biotech, INC. | $29.36 | 2025 | |
| Alnylam Pharmaceuticals INC. | $28.94 | 2023 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $25.72 | 2021 | |
| Averitas Pharma INC. | $23.96 | 2024 | Qutenza |
| Genzyme Corporation | $23.01 | 2023 | |
| Medtronic, INC. | $20.62 | 2025 | Inceptiv |
| Cala Health, INC. | $18.67 | 2023 | Cala Trio |
| Zogenix INC. | $16.87 | 2021 | |
| Cycle Pharmaceuticals INC | $14.95 | 2025 | Tascenso Odt |
| Assertio Therapeutics, INC. | $14.74 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.71 | 2022 | |
| Ge Healthcare | $14.53 | 2021 | |
| Tanabe Pharma America, INC. | $13.37 | 2022 | |
| Life Molecular Imaging LTD | $12.57 | 2024 | Neuraceq |
| Allergan, INC. | $11.25 | 2021 | |
| Aucta Pharmaceuticals, INC. | $3.82 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Van Gerpen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.